10 Pharmacists who are aware of cases of exenatide-associated acute pancreatitis or other serious adverse drug reactions are encouraged to report their findings to MedWatch, the FDAs adverse drug reporting program (www.fda.gov/Safety/MedWatch/ Anti-exenatide Antibodies: In phase III clinical trials, 41% to 49% of patients receiving exenatide developed anti-exenatide antibodies
Isotope patterns: Natural isotope distribution creates characteristic patterns in mass spectra
Food and Drug Administration (FDA) issued new label warnings for Ozempic, indicating that it can increase the risk of intestinal blockages
Basic monitoring should include the parameters tracked in clinical trials: body weight, waist circumference, blood pressure, resting heart rate, and subjective GI symptom assessment
Choosing Between GLP-1 and Dual Agonist Medications Armed with understanding of GLP-1 versus GIP, how do you decide which medication type to use
Shi Q, Nong K, Vandvik PO, Guyatt GH, Schnell O, Rydn L, et al
